The UCLA trial is currently enrolling patients. Clinical trial compares two targeted radiation therapies for recurrent prostate cancer. New AI tool, ProCUSNet, detects prostate cancer more accurately ...

Non-inferior salvage treatment–free survival at 30 months favored HIFU (90%) versus salvage radical prostatectomy (86%), ...

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the ...

BALTIMORE, May 12, 2026 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2026 amendment to the Advanced ...

SAN FRANCISCO -- For patients with recurrent prostate cancer, those with a certain subtype had clinically meaningful benefits when apalutamide (Erleada) was added to salvage radiotherapy after radical ...

If you or a loved one are navigating the journey of prostate cancer, you know that every decision weighs heavily. You’ve likely faced surgery or initial treatments, only to encounter the fear that ...

A new phase 3 trial reveals that combining enzalutamide and leuprolide significantly improves overall survival for men with ...

Men with recurrent prostate cancer following surgery or radiation therapy may now have a new chance to live longer. A massive global trial has found that a combination of two medications, enzalutamide ...

Please provide your email address to receive an email when new articles are posted on . A genetic test that identifies the PAM50 biomarker predicted which patients with recurrent prostate cancer would ...

Men whose prostate cancer returns after surgery or radiation therapy may now benefit from a new drug combination shown in clinical trials to cut the risk of death by more than 40%. The combination ...

Adding the drug enzalutamide to standard hormone therapy reduced deaths by more than 40% in men with recurrent prostate cancer. The international study, published in The New England Journal of ...